

Innovotech, Inc.
Suite L131, 2011 – 94 Street
Edmonton, Alberta
T6N 1H1

NEWS RELEASE

Innovotech Reports Issue of U.S. Patent No. 10,434,210 for Antimicrobial Silver Compounds in Gels

Edmonton, October 18, 2019. Innovotech Inc. (IOT, TSX-V), is pleased to report that its invention for use of antimicrobial silver compounds, including InnovoSIL™-1 and AgreGuard™-1, in a variety of formulations was issued as U.S. Patent No. 10,434,210 on October 8, 2019.

The patent covers the incorporation of these silver compounds into various materials including gels, ointments, creams, foams, and polymers, where they demonstrate unprecedented stability combined with sustained antimicrobial activity. Dr. Patricia Nadworny, Innovotech's Quality and Safety Director, who was the chief scientist involved in developing these formulations said, "These antimicrobial silver formulations could be used in numerous situations where biofilm infections are of concern, including in wound healing; on surgical or medical instruments; in disinfection of work/processing surfaces; on medical devices such as catheters, endoscopes, endotracheal tubes, implants, and many others; and for direct application to infected tissue, leaves or seeds". These formulations improve adherence and consistency of application to surfaces.

InnovoSIL™-1, AgreGuard™-1, and related silver compounds covered by this patent are broadly effective against bacterial and fungal biofilms associated with human, animal, and plant infections, and eliminate infections via multiple mechanisms of action, making it difficult for microbial resistance to develop.

The issue of this patent allows Innovotech to license these applications of antimicrobial silvers to industry partners interested in enhancing the antibiofilm activity of their products, as well as to continue with in-house product development.

Dr. James Timourian
President
INNOVOTECH INC.
780.448.0585

This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company's exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.